In 2018, the value of six biomedical M & A cases exceeded US $3 billion

[China Pharmaceutical network industry trends] in 2018, pharmaceutical and biological enterprises have been continuously merging According to incomplete statistics, this year, there were 13 biomedical M & A cases worth more than US $1 billion Among them, there are 6 M & A cases worth more than US $3 billion Takeda's plan to acquire shire, which lasted for more than a month, was finally settled in May The board of directors of the two companies has reached an agreement on the recommended offer, and Takeda will acquire shire for 46 billion pounds (about 62 billion US dollars) It is reported that this is also a large-scale overseas acquisition of Japanese companies With the leading position of the two companies in the priority treatment field, strong geographical coverage, larger scale and efficiency, and more R & D engines, the combined team will be able to better provide highly innovative drugs and transformative care for patients around the world, so as to bring them better health Sanofi's $11.6 billion acquisition of bioverativ in January resulted in a final deal between Sanofi and bioverativ, a biopharmaceutical company focused on hemophilia and other rare blood disease therapies The deal will strengthen Sanofi's important role in the treatment of rare diseases Sanofi lost in 2016 by buying California cancer expert medivation topfizer, and missed actelion, a Swiss biotech company acquired by Johnson & Johnson last year "With biooverativ, we welcome the hemophilia market," said Olivier brandicourt, executive director of Sanofi Celgene's purchase of Juno therapeutics: US $9 billion this year, celgene purchased Juno therapeutics for us $87 per share and a total value of US $9 billion According to relevant analysis, immunotherapy drug sales are expected to reach US $28 billion in 2021 Celgene has already been involved in this acquisition This acquisition shows celgene's ambition to become an industry and seek the next blockbuster therapy In addition, after the loss in the third quarter of last year, celgene's shareholders are eager to seek forward earnings growth; jcar017, which Juno plans to list in 2020, has the potential to become the best in class therapy for relapsed DLBCL, and is expected to bring annual revenue of US $30 billion Novartis's acquisition of avexis trading price: $8.7 billion according to the terms, Novartis will pay $218 per share of avexis shares, an 88% premium to the closing price of the shares last Friday Novartis said it hopes to expand its leadership in gene therapy and neuroscience through the acquisition Affected by the R & D investment, the acquisition is expected to slightly affect the revenue of this year and next two years, but in 2020, it will significantly boost its operating income and profitability Analysts believe that Novartis's acquisition of avexis has made the main company in gene therapy business increasingly "hot", and regenxbio, which focuses on gene therapy of mumps related viruses, and uniqure, which is engaged in gene therapy for rare diseases, are likely to be acquired in the future The two companies rose 15.63% and 16.44% respectively on September 9 Xinji's acquisition of impact Biosciences transaction price: 7 billion US dollars on January 7, celgene announced that it would acquire impact biomedicines with an additional 7 billion US dollars In the past two weeks, it has announced that it will acquire its partner Juno therapeutics with 9 billion US dollars, which is a large amount of acquisition at present It is reported that Xinji has held nearly 10% of Juno's shares before, and this acquisition will show Xinji's determination to enter the field of car-t therapy by virtue of Juno's position in the industry of car-t therapy, which is an important step in its strategic layout Transaction price of Sanofi's acquisition of Ablynx: on January 29, 3.9 billion euros, Sanofi signed a final agreement with Ablynx, a Belgian pharmaceutical company, to successfully acquire Ablynx with a total price of 3.9 billion euros (4.8 billion US dollars) and 45 euros per share, becoming the second major acquisition launched by Sanofi in January The transaction was unanimously approved by the board of directors of both sides In fact, Novo Nordisk has long coveted Ablynx, but it was rejected by Ablynx because of its 2.6 billion euro offer, which was defeated by Sanofi Finally, Ablynx chose Sanofi It is understood that before the acquisition, Ablynx has been cooperating with world-renowned pharmaceutical giants, including Albright, bringer Ingelheim, Yiteng pharmaceutical, Novartis, Novo Nordisk, Merck, MSD, Sanofi, Japan Dazheng pharmaceutical, etc.